Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243279 | 0.98 | GFER (0.38) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL2245856 | 0.94 | GFER (0.41) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL2247757 | 0.74 | HDAC8 (0.36) | GFERKDM4EGAAHDAC8 | |
| SCHEMBL2246612 | 0.73 | HDAC8 (0.35) | GFERKDM4EGAAHDAC8MAPT | |
| SCHEMBL639462 | 0.71 | KDM4E (0.53) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL638653 | 0.70 | KDM4E (0.51) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL16534025 | 0.69 | BACE1 (0.34) | — | |
| SCHEMBL2243791 | 0.68 | GFER (0.41) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL639698 | 0.67 | GFER (0.51) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL2246622 | 0.67 | HDAC8 (0.38) | GFERKDM4EGAAHDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989483-B2 | 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-08-02 | — | — | US | claimed |
| US-20100144813-A1 | NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | claimed |
| EP-2164845-A1 | NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | Galderma Research & Development (FR) | 2010-03-24 | — | — | EP | claimed |
| WO-2008152332-A1 | NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | claimed |
| US-7989483-B2 | 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-08-02 | — | — | US | disclosed |
| US-20100144813-A1 | NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2164845-A1 | NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | Galderma Research & Development (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152332-A1 | NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144813-A1 | NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | TYR, TH, NAT1 | GFER 2476/4885KDM4E 1277/4885GAA 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.